PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 10 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 10 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 1 year 10 months ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 10 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 10 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
BRIEF published on 06/19/2024 at 13:05, 1 year 10 months ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 10 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 10 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 1 year 10 months ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 10 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 05/14/2026 at 15:10, 1 hour 22 minutes ago Banyan Provides Summary of 2025 Diamond Drill Program for the Flagship AurMac Project, Yukon, Canada
Published on 05/14/2026 at 15:00, 1 hour 32 minutes ago Karbon-X Explores Clean Cooking and Fish Smoking Climate Initiative Concept in Senegal
Published on 05/14/2026 at 15:00, 1 hour 32 minutes ago ACCESS Newswire Celebrates PRSSA Bateman Competition Success and the Next Generation of Communications Leaders
Published on 05/14/2026 at 14:50, 1 hour 42 minutes ago Germany's BGR Assesses NextSource Materials' Molo Graphite Mine as Part of Federal Critical Minerals Study
Published on 05/14/2026 at 14:30, 2 hours 2 minutes ago Boron One Holdings Inc. Completes Its Jarandol Basin Exploration Program for 2026
Published on 05/14/2026 at 16:15, 17 minutes ago Fibank successfully closed a record-breaking international placement for a Bulgarian bank, raising a total of EUR 310 million across two bond issues
Published on 05/14/2026 at 14:55, 1 hour 37 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 05/14/2026 at 14:54, 1 hour 38 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 05/14/2026 at 14:53, 1 hour 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 05/14/2026 at 09:03, 7 hours 29 minutes ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 22 hours 30 minutes ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
Published on 05/13/2026 at 18:00, 22 hours 32 minutes ago ALTAREIT - Assemblée Générale Mixte du 4 juin 2026 - Modalités de mise à disposition des documents préparatoires
